The Oral Vaccine Successfully Produced Antibodies in a
Preclinical Study After a Single Dose
NEW YORK, March 19, 2021 /PRNewswire/ --
- Good candidate for protection against COVID variants due
to triple antigen targeting
- Implications for potential ease of widescale distribution
and administration anytime, anywhere for oral COVID-19
vaccine
- Efficacy following a single oral dose administration in
preclinical study
- Clinical trial expected to commence Q2
2021
- Watch video
- Successful expansion of Oramed's
POD™ oral delivery technology into the lucrative
vaccine development market
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP)
(www.oramed.com), a clinical-stage pharmaceutical company focused
on the development of oral drug delivery systems, announced today
that it has entered into definitive agreements to form a joint
venture focused on the development of novel oral COVID-19
vaccines. The new company, Oravax Medical Inc., is based on
Oramed's proprietary POD™ oral delivery
technology and Premas Biotech Pvt. Ltd.'s novel vaccine
technology.
Oravax's COVID-19 vaccine candidate benefits from being a virus
like particle (VLP) triple antigen vaccine that targets three
structural proteins, which should make it a better candidate for
protection across emerging mutations of the coronavirus. The
oral delivery of the vaccine should allow for widescale inoculation
and easier distribution of the vaccine without requiring an
injection.
In a pilot animal study, the oral COVID-19 vaccine promoted both
systemic immunity through Immunoglobulin G (IgG), the most common
antibody in blood and bodily fluids that protects against viral
infections, and Immunoglobulin A (IgA).
Oravax anticipates commencing a clinical study during the second
quarter of 2021.
"An oral COVID-19 vaccine would eliminate several barriers to
rapid, widescale distribution, potentially enabling people to take
the vaccine themselves at home. While ease of administration is
critical today to accelerate inoculation rates, an oral vaccine
could become even more valuable in the case that a COVID-19 vaccine
may be recommended annually like the standard flu shot," said
Nadav Kidron, CEO of Oramed.
About Oravax Medical Inc.
Oravax was established in 2021 by Oramed Pharmaceuticals Inc.,
the largest shareholder in Oravax, along with Premas Biotech
and certain other shareholders with a mission to bring an
oral COVID-19 vaccine to the market. Oravax combines cutting
edge vaccine technology acquired from Premas Biotech and the
proprietary POD™ oral delivery technology of Oramed
Pharmaceuticals. For more information, please visit
www.ora-vax.com
About Oramed Pharmaceuticals
Oramed
Pharmaceuticals is a platform technology pioneer in the field
of oral delivery solutions for drugs currently delivered via
injection. Established in 2006, with offices in the United
States and Israel, Oramed has developed a novel Protein
Oral Delivery (POD™) technology. Oramed is seeking to revolutionize
the treatment of diabetes through its proprietary lead
candidate, ORMD-0801, which has the potential to be the first
commercial oral insulin capsule for the treatment of
diabetes. The Company has completed multiple Phase II clinical
trials under an Investigational New Drug application with
the U.S. Food and Drug Administration. In addition, Oramed is
developing an oral GLP-1 (Glucagon-like peptide-1) analog
capsule, ORMD-0901.
For more information, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the expected timing of a
clinical study for the Oravax vaccine, the potential for Oravax's
vaccine in development to be a better candidate for protection
against COVID-19, the potential for ease of distribution, including
at home, the potential value of an oral vaccine, the potential
timing of clinical trials, the potential of ORMD-0801 to be the
first commercial oral insulin capsule for the treatment of diabetes
or revolutionizing the treatment of diabetes with our products. In
addition, historic results of scientific research and clinical
trials do not guarantee that the conclusions of future research or
trials will suggest identical or even similar conclusions. These
forward-looking statements are based on the current expectations of
the management of Oramed only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements,
including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact
Estee
Yaari
+1-844-9-ORAMED Ext: 2
estee@oramed.com
Logo -
https://mma.prnewswire.com/media/647544/Oramed_Pharmaceuticals_Logo.jpg